BENGALURU (Reuters) – Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by revenue, on Friday reported a 29.6% rise in fourth-quarter profit, as it benefited from lower expenses.
The company’s consolidated profit before exceptional items and tax rose to 24.11 billion rupees ($291.7 million) for the quarter ended March 31, it said in an exchange filing.
Input costs declined 13.2% for the quarter.
($1 = 82.6420 Indian rupees)
(Reporting by Rama Venkat in Bengaluru; Editing by Varun H K)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.